Corbion Strategy Update of ‘Advance 2025’
December 01 2022 - 1:00AM
Corbion Strategy Update of ‘Advance 2025’
During its Capital Markets Day for analysts and
investors in Amsterdam today, Corbionmanagement
will present an update of
the ‘Advance
2025’ strategy
progress and introduce
updated targets for the 2023-2025 period. Through
our purpose
‘Preserve what matters’,
sustainability continues to be at the
forefront in all our
decision-making.
Key highlights of the event will include:
- Significant progress made in delivering ‘Advance 2025’
- Creation of Algae Ingredients as a new business unit, following
commercial breakthrough
- Increase of net sales growth(1) target to 5-8%(2) p.a. for
2023-2025, up from 4-7% p.a.
- Adjusted EBITDA growth(1) target of 15-20% p.a. for
2023-2025
- Improving funding ratio(3) to below 2.9x in 2023, and 1.5-2.5x
from 2024
- Divestment process for non-core emulsifiers business
initiated
We are well on track in delivering the Advance 2025 strategy,
navigating through a highly volatile business climate. We raised
our organic sales growth rate substantially, grew our Adjusted
EBITDA, invested in our organization and production capacity,
exited from all non-core manage-for-exit activities, achieved
break-even EBITDA in algae-based omega-3, and raised our carbon
footprint reduction target in line with 1.5 degrees. Today, we mark
the beginning of the second phase of our Advance 2025 strategy.
After achieving the break-even EBITDA level in June 2022 as
anticipated, we believe now is the time to carve out Algae
Ingredients from the Incubator into a separate business unit. This
expresses our confidence in the growth and profitability potential
of this business line. Initially, this business unit will consist
of our algae-based omega-3.
We are raising our organic net sales growth(1) guidance for the
2023-2025 period from 4-7% to 5-8%(2) p.a. We are switching from a
margin target to an organic Adjusted EBITDA growth target (15-20%
annually), as we believe this is a better measure of our
performance, given the highly volatile input cost dynamics. We are
aiming for a € 250 million Adjusted EBITDA for our core activities
by 2025(4).
We expect to improve our funding ratio(3) to 2.9-3.2x by end of
2022, below 2.9x in 2023, and between 1.5x and 2.5x from 2024
onwards, irrespective of divestments or acquisitions. Within this
funding framework we will continue to invest significantly to
support our profitable growth opportunities in all of our business
units.
We have initiated the process of divesting our non-core
emulsifier business enabling us to fully focus on profitably
growing our core business. In 2020 we categorized the emulsifier
business as non-core: ‘manage-for-value’. The emulsifier business
has delivered a very strong performance over the past few years,
and we have become the market leader in the US emulsifier
market.
TotalEnergies and Corbion are committed to growing the PLA
business. We are in discussion to explore several operational and
financial models regarding the future lactic acid requirements for
the production of PLA in Grandpuits.
Financial guidance 2023-2025
Financial targets
2023-2025 (for core
activities)
- Organic net sales growth 5-8%(2) p.a.
- Organic Adjusted EBITDA growth 15-20% p.a.
Underlying ambitions
- Organic net sales growth Sustainable Food Solutions 5%(2)
p.a.
- Organic net sales growth Lactic Acid & Specialties 7%(2)
p.a.
- Organic net sales growth Algae Ingredients 25%(2) p.a.
- EBITDA investments of other Incubator initiatives: 0.5-1.5% of
Corbion core sales p.a.
- Capex: €160 million average per annum
- Covenant net debt/covenant EBITDA: Target range 1.5-2.5x
- ROCE > WACC
- 20221201 Corbion PR ENG final
Corbion N.V (EU:CRBN)
Historical Stock Chart
From Nov 2024 to Dec 2024
Corbion N.V (EU:CRBN)
Historical Stock Chart
From Dec 2023 to Dec 2024